ArticleScientific reports2025
The effect of cuproptosis-related gene Atox1 on cardiac hypertrophy in heart failure was investigated based on bioinformatics analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) represents the final stage of multiple cardiovascular diseases. Cuproptosis may play an important role in the progression of HF. This study aimed to identify cuproptosis-related biomarkers in HF and elucidate their potential regulatory mechanisms. We downloaded the HF-related bulk dataset from the GEO database for performing WGCNA and differential analysis. A total of 5,563 HF-related co-expressed genes were identified. By intersecting the above genes with cuproptosis-associated genes, we identified three candidates (DBT, Atox1 and DLD) that are potentially involved in cardiac hypertrophy in HF. Among them, DBT and DLD were lowly expressed whereas Atox1 was highly expressed in the disease group. We selected Atox1 for subsequent analysis. Transverse aortic constriction (TAC) method was applied for establishing a mouse model of HF-associated cardiac hypertrophy. In the model mice, we found significantly overexpressed Atox1 (fold change = 3.47) by qRT-PCR and increased levels of cuproptosis marker proteins SLC31A1 and FDX1 as well as Dlat aggregation. To further examine the action mechanism of Atox1, cardiomyocytes (H9c2) were treated with Ang II to simulate cardiac hypertrophy in vitro, followed by ATOX1 knockdown. It was found that low expression of Atox1 inhibited cuproptosis and suppressed cardiomyocyte hypertrophy. When cuproptosis was activated in Ang II + si-Atox1 group using elesclomol + CuCl
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.